Stem cell-based ischemic stroke therapy:Novel modifications and clinical challenges  

作　　者：Yuankai Sun Xinchi Jiang Jianqing Gao 

机构地区：[1]Institute of Pharmaceutics,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China [2]Hangzhou Institute of Innovative Medicine,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China [3]Dr.Li Dak Sum&Yip Yio Chin Center for Stem Cell and Regenerative Medicine,Zhejiang University,Hangzhou 310058,China [4]Department of Pharmacy,The Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China

出　　处：《Asian Journal of Pharmaceutical Sciences》2024年第1期18-34,共17页亚洲药物制剂科学（英文）

基　　金：supported by the National Natural Science Foundation of China(U22A20383,82003668);the Natural Science Foundation of Zhejiang Province(LD22H300002,LQ21H300002);Ningbo Technology Innovation 2025 Major Special Project(2022Z150).

摘　　要：Ischemic stroke(IS)causes severe disability and high mortality worldwide.Stem cell(SC)therapy exhibits unique therapeutic potential for IS that differs from current treatments.SC’s cell homing,differentiation and paracrine abilities give hope for neuroprotection.Recent studies on SC modification have enhanced therapeutic effects for IS,including gene transfection,nanoparticle modification,biomaterial modification and pretreatment.Thesemethods improve survival rate,homing,neural differentiation,and paracrine abilities in ischemic areas.However,many problems must be resolved before SC therapy can be clinically applied.These issues include production quality and quantity,stability during transportation and storage,as well as usage regulations.Herein,we reviewed the brief pathogenesis of IS,the“multi-mechanism”advantages of SCs for treating IS,various SC modification methods,and SC therapy challenges.We aim to uncover the potential and overcome the challenges of using SCs for treating IS and convey innovative ideas for modifying SCs.

关 键 词：Ischemic stroke Stem cell therapy Stem cell modification Cell therapy challenge 

分 类 号：R943[医药卫生—药剂学]